Hancock Jaffe Laboratories (NSDQ:HJLI) said today that Colombia’s Ethics Committee at Fundación Santa Fe de Bogotá approved a first-in-human trial of its VenoValve bioprosthetic valve. The Irvine, Calif.-based company’s VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves […]
hancockjaffelabs
Natus Medical lifts Kennedy to the corner office | Personnel Moves – July 17, 2018
Natus Medical (Nasdaq: BABY) said last week that its current CEO Jim Hawkins is retiring from their position, with current chief financial officer Jonathan Kennedy slated to take over as prez & chief exec. Kennedy has operated as CFO since April 2013, while the retiring Hawkins spent 14 years as the chief exec, the Pleasanton, Calif.-based company said. […]
Over-allotment takes Hancock Jaffe IPO to nearly $9m
The underwriter of an initial public offering by Hancock Jaffe Laboratories (NSDQ:HJLI) this week exercised in full its over-allotment option, taking the gross proceeds from the flotation to nearly $9 million. The IPO, which priced on the last day of May, initially brought in $7.5 million for Irvine, Calif.-based Hancock Jaffe, which makes bioprosthetic implants designed to treat chronic […]
Hancock Jaffe prices $8m IPO below the range
Medical device developer Hancock Jaffe Laboratories yesterday priced its initial public offering below the re-set range it issued last week, raising nearly $8 million. Irvine, Calif.-based Hancock Jaffe makes bioprosthetic implants designed to treat chronic deep vein insufficiency, heart valve conditions and coronary artery bypass graft. Last December the company said it planned to float nearly 1.9 million shares at $6 […]
Hancock Jaffe re-sets the range for $8m IPO
Medical device developer Hancock Jaffe Laboratories yesterday re-set the range on a pending initial public offering, which would fetch roughly $8 million at the midpoint. Irvine, Calif.-based Hancock Jaffe makes bioprosthetic implants designed to treat chronic deep vein insufficiency, heart valve conditions and coronary artery bypass graft. Last December the company said it planned to float nearly 1.9 million […]
Hancock Jaffe Labs files for $13m IPO
Medical device developer Hancock Jaffe Laboratories this week set the range on a pending initial public offering, which would fetch roughly $13 million at the midpoint. Irvine, Calif.-based Hancock Jaffe makes bioprosthetic implants designed to treat chronic deep vein insufficiency, heart valve conditions and coronary artery bypass graft. The company said it plans to float nearly 1.9 […]